ABTRACT OBJECTIVES: To undertake a preliminary assessment of the potential for CT measures of tumour heterogeneity to stratify risk of nodal metastasis in patients with non-small cell lung cancer (NSCLC).
METHODS: Tumour heterogeneity in CT images from PET/CT examinations in 150
consecutive patients with NSCLC was assessed using CT texture analysis. The short axis diameter of the largest mediastinal node was also measured. 42 patients without distant metastases subsequently had tumour nodal status confirmed by surgery (n=26) or Endobronchial Ultrasound (EBUS); n=16). CTTA parameters and largest nodal diameter were related to nodal status using the rank-correlation and the risk-ratio for each nodal stage (>N0, >N1, >N2) was compared between patients categorised as high and low risk by CTTA or nodal size. The most significant predictor of nodal status was related to overall survival using Kaplan-Meier analysis. RESULTS: N-stage was more significantly correlated with CTTA than nodal diameter (Rs = -0.39, p = 0.011, Rs = -0.45, p=0.0025, Rs = -0.40, p=0.0091 for normalised SD, guided TBNA should be offered to patients with a high probability of mediastinal 20 malignancy (85%; lymph nodes > 20 mm maximum short axis on CT). New methods 21 that can improve the risk stratification for mediastinal disease based on CT therefore have the potential to improve the selection of staging procedures for patients with 23 NSCLC. 24 CT texture analysis (CTTA) is emerging as a technique for derivation of prognostic 25 biomarkers for patients with NSCLC and other tumours (2-5). CT texture analysis 26 evaluates quantitatively the distribution of CT attenuation values within a tumour to 27 determine its heterogeneity. Tumour heterogeneity has been shown to relate to 28 tumour aggression and treatment response, with hypoxia, mutations in EGFR and 29 KRAS genes, and ALK gene re-arrangements having been identified as potential 30 biological correlates for CTTA values in NSCLC (2). Given the prognostic significance 31 of CTTA and its associated biological characteristics, we hypothesize that CTTA can 32 stratify risk for nodal metastatic disease in patients with NSCLC. In this study we investigated the potential for CT measures of tumour heterogeneity to 107 stratify risk of nodal disease in patients with NSCLC. CTTA parameters within the primary 108 tumour were found to be superior predictors of nodal stage >0 and nodal >1 than the 109 measurement of mediastinal nodal diameter as currently recommended by NICE. However, 110 mediastinal nodal diameter was the best predictor for N-stage >2. The finding that the 111 presence of two or more high-risk CTTA values is not only associated with a greater risk of nodal stage >1 but also reduced survival, indicates that the presence nodal disease inferred 113 by high-risk CTTA values is of clinical importance. 114 CTTA has the potential to determine the optimum strategy for investigation of nodal disease 115 more accurately than measurements of mediastinal nodal diameter as currently 116 recommended by NICE. For example, the NICE guidance would recommend the nodal status 117 for the patient with N2 disease illustrated in Figure 1 be determined by PET-CT alone. While 118 PET CT is a non-invasive method in assessing for mediastinal nodal metastasis, its sensitivity 119 and specificity of detecting mediastinal metastasis is only around 77% and 86% 120 respectively(6). Furthermore the sensitivity of PET for detecting nodal metastasis is lower 121 when the size of the lymph node is less than 10mm (7) . A PET/CT only strategy for this 122 patient would have resulted in underestimation of disease status whereas the presence of 123 high-risk CTTA parameters could feasibly have indicated the need for nodal sampling prior to 124 surgery. Similarly, due to the presence of an enlarged mediastinal node, the NICE guidance 125 would recommend nodal sampling be considered for the patient with N0 disease illustrated 126 in Figure 2 whereas this procedure may not have been considered necessary based on the 127 absence of high-risk CTTA values. As the NICE strategies were optimised on the basis of cost-128 effectiveness, CTTA therefore also has potential health economic benefits. 129
The observation that tumours with increased metastatic potential exhibit greater genetic 130 instability (8) provides a biological basis for a relationship between CT measures of tumour 131 heterogeneity and nodal status. In the presence of genetic instability, the evolutionary 132 dynamics of tumour development may result in the co-existence of genetically distinct sub-133 clones within the same tumour (9). For these sub-clones to be detected by CT the genetic 134 status of the sub-clone must correspond to one or more phenotypic features demonstrable 135 by imaging. Furthermore, the spatial separation between sub-clones needs to be sufficiently be met by radiogenomic studies demonstrating correlations between genomic aberrations 138 and specific CT features in NSCLC and other tumours (5, 10-15). Spatial separation of sub-139 clones has also been reported and may be sufficiently large to result in sampling error during 140 image-guided biopsy (9). Although plausible, a direct connection between genomic 141 instability, metastatic potential and CT measures of tumour heterogeneity remains to be 142 demonstrated empirically. 143
The main limitation of our study is the small size of our cohort of NSCLC patients without 144 distant metastases for whom nodal status had been confirmed either at surgery or 145 endobronchial biopsy. Larger multi-centre studies are required to confirm our findings. To 146 minimise potential bias, we have adopted median textures as the thresholds for the 147 categorisation of high and low risk for nodal metastases. Larger studies would also allow 148 optimisation of these threshold values through use of separate training and evaluation 149 cohorts. We have also adopted a single slice approach to assess for tumour heterogeneity 150 which has the potential to miss regions of greater heterogeneity and hence under estimate 151 the risk of nodal metastasis (3). The consistency of risk stratification by CTTA may also be 152 potentially improved through automated CT ROI definition based on the PET component of 153
PET/CT examinations(16). 154
The potential prognostic value of CTTA in NSCLC was first reported in 2012 (17) but as yet 155 this finding has not been translated into a widely adopted clinical application. It has been 156 proposed that the prognostic information afforded by CTTA could be used to identify 157 patients with a greater risk for post-surgical recurrence who might benefit most from 158 adjuvant chemotherapy, or to recognise those patients with advanced disease who are 159 unlikely to get sufficient survival benefit to justify the morbidity of chemotherapy in a 160 palliative setting (2). However, the use of CT as a prognostic biomarker represents a novel 161 application for imaging in the management of NSCLC, and in cancer care in general; a fact that may represent a block to the adoption of CTTA into clinical practice. On the other hand, 163 the use of CT markers to assess risk of mediastinal malignancy is embedded within the 164 current clinical guidelines published by NICE. The replacement of measurements of 165 mediastinal nodal size by CTTA measurements of tumour heterogeneity would simply 166 represent a development of an established concept and may therefore be more readily 167 adopted into clinical practice. 168
In summary, CTTA in NSCLC is related to nodal status in patients without distant 169 metastases and has the potential to inform selection of investigative strategies for 170 the assessment of mediastinal malignancy. 
HIGHLIGHTS
 CT texture analysis (CTTA) is emerging as a technique for derivation of prognostic biomarkers for patients with NSCLC  CT texture analysis evaluates quantitatively tumour heterogeneity, which is linked to tumour aggression.
 CTTA in NSCLC is related to nodal status in patients without distal metastases and has potential to inform selection of investigative strategies for the assessment of mediastinal malignancy.
